nav-left cat-right
cat-right

Key hep C protein revealed

In a discovery that could put a vaccine for hepatitis C closer in sight, researchers have been able to characterize a key protein in the virus that aids infection in the liver. The structure of the protein, known as E2 envelope glycoprotein, has up until now evaded scientists. But the new, detailed picture of the protein obtained by investigators at The Scripps Research Institute in La Jolla, CA, is an important development...

Roche has extended its serology panel to include a...

With an estimated 216,000 individuals chronically infected in the UK (England 161,000, Northern Ireland 4,000, Scotland 39,000, Wales 12,000), hepatitis C (HCV) remains a major public health problem; and HCV-related end stage liver disease and mortality continue to increase1. The Health Protection Agency states that it is necessary to sustain and enhance efforts to raise awareness, prevent new infections, increase diagnosis,...

Scripps Florida scientists to create new screening...

Scientists from the Florida campus of The Scripps Research Institute have been awarded just over $1 million from the National Institutes of Health for a three-year study to develop new high-throughput screening tests to find compounds that disable a protein essential to hepatitis C virus (HCV) replication. Timothy Tellinghuisen, a Scripps Florida associate professor, is the principal investigator for the study. Hepatitis C is...

New Drug Effectively Treats Hepatitis C

WEDNESDAY, June 22 (HealthDay News) — The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show. The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C virus can lurk in the body for years, causing liver...

Evotec Expands Collaboration with InterMune

Hamburg, Germany | Oxford, UK- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a second drug discovery contract with Evotec. Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further...

Bucks County’s Institute for Hepatitis and V...

New Hope, PA — (SBWIRE) — 10/10/2007 — Bucks County’s Institute for Hepatitis and Virus Research (IHVR) and BioLeap have entered into a collaboration to develop new therapeutic compounds for the treatment of Hepatitis C. Up to 50% of patients treated with current standard therapies do not respond adequately and often suffer serious side effects from the drugs. Thus there is a critical need for new...